Curis (CRIS) Return on Capital Employed (2011 - 2026)
Curis' (CRIS) quarterly Return on Capital Employed came in at 71.81% in Q1 2026, up 13747.0% YoY from N/an in Q1 2025, and down 22.28% on a QoQ basis from 58.73% in Q4 2025.
Curis (CRIS) Return on Capital Employed (2011 - 2026) Analysis & Trends
Curis (CRIS) has 16 years of Return on Capital Employed data on file, last reported at 71.81% in Q1 2026.
- Quarterly Return on Capital Employed rose 13747.0% year-over-year to 71.81% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 71.81% (up 13747.0% YoY) and the FY2025 annual result came in at 34.54%, up 7613.0% from the prior year.
- Return on Capital Employed slipped to 71.81% in Q1 2026, from 58.73% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 34.12% in Q1 2022 to a low of 402.63% in Q3 2025.
- A 5-year average of 119.77% and a median of 71.81% in 2026 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed slumped 20702 bps — and 2026, when it soared 13747 bps.
- Tracing CRIS's Return on Capital Employed over 5 years: stood at 50.1% in 2022, then slumped by 57 bps to 78.45% in 2023, then tumbled by 149 bps to 195.0% in 2024, then surged by 70 bps to 58.73% in 2025, then slipped by 22 bps to 71.81% in 2026.
- The last three Return on Capital Employed figures came in at 71.81% (Q1 2026), 58.73% (Q4 2025), and 402.63% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Curis | 3.27 Mn | -2.35 Mn | - | -82.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -71.81% |
| Dec 31, 2025 | -58.73% |
| Sep 30, 2025 | -402.63% |
| Jun 30, 2025 | -254.69% |
| Mar 31, 2025 | -209.28% |
| Dec 31, 2024 | -195.00% |
| Sep 30, 2024 | -195.61% |
| Jun 30, 2024 | -134.45% |
| Mar 31, 2024 | -84.27% |
| Dec 31, 2023 | -78.45% |
| Sep 30, 2023 | -63.12% |
| Jun 30, 2023 | -58.43% |
| Mar 31, 2023 | -52.88% |
| Dec 31, 2022 | -50.10% |
| Sep 30, 2022 | -49.39% |
| Jun 30, 2022 | -43.06% |
| Mar 31, 2022 | -34.12% |
| Dec 31, 2021 | -27.36% |
| Sep 30, 2021 | -21.40% |
| Jun 30, 2021 | -17.10% |